Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Sotera Health Company (SHC)
Consensus Price Target: $22.72 (23.8% implied return)
With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use.
Why Does SHC Fall Short?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Modest revenue base of $1.22 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
- Investment activity picked up over the last five years, pressuring its weak free cash flow margin of 0.8%
At $18.36 per share, Sotera Health Company trades at 17.8x forward P/E. Check out our free in-depth research report to learn more about why SHC doesn’t pass our bar.
CooperCompanies (COO)
Consensus Price Target: $66.21 (22.8% implied return)
With a history dating back to 1958 and a portfolio spanning two distinct healthcare segments, Cooper Companies (NASDAQ: COO) develops and manufactures medical devices focused on vision care through contact lenses and women's health including fertility products and services.
Why Does COO Give Us Pause?
- Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
- Estimated sales growth of 2.9% for the next 12 months implies demand will slow from its two-year trend
- ROIC of 4.7% reflects management’s challenges in identifying attractive investment opportunities
CooperCompanies is trading at $53.93 per share, or 11.9x forward P/E. If you’re considering COO for your portfolio, see our FREE research report to learn more.
GoodRx (GDRX)
Consensus Price Target: $4.03 (20% implied return)
Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ: GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.
Why Do We Pass on GDRX?
- Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
- Subscale operations are evident in its revenue base of $785.2 million, meaning it has fewer distribution channels than its larger rivals
- Underwhelming -0.4% return on capital reflects management’s difficulties in finding profitable growth opportunities
GoodRx’s stock price of $3.36 implies a valuation ratio of 10.1x forward P/E. To fully understand why you should be careful with GDRX, check out our full research report (it’s free).
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
